Publications – Heine Laboratory

2024

Rapid protection against viral infections by chemokine-accelerated post-exposure vaccination

Heine A., Lemmermann N.A.W., Flores C., Becker-Gotot J., Garbi N., Brossart P., Kurts C. Front Immunol. 2024 Jan DOI:10.3389/fimmu.2024.1338499

2023

Early combination therapy of COVID-19 in high-risk patients

Orth HM, Flasshove C, Berger M, Hattenhauer ST, Biederbick KD, Mispelbaum R, Klein U, Stemler J, Fisahn M, Doleschall AD, Baermann BN, Koenigshausen E, Tselikmann O, Killer A, de Angelis C, Gliga S, Stegbauer J, Spuck N, Silling G, Rockstroh JK, Strassburg CP, Brossart P, Panse JP, Jensen BO, Luedde T, Boesecke C, Heine A, Cornely OA, Monin MB.Infection. 2023 Nov 29. doi: 10.1007/s15010-023-02125-5. Online ahead of print.PMID: 38017344

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer

Heine A, Held SAE, Daecke SN, Flores C, Brossart P.Front Immunol. 2023 Sep 26;14:1257017. doi: 10.3389/fimmu.2023.1257017. eCollection 2023.PMID: 37822928

Optimized Conformal Total Body Irradiation with VMAT Using a Linear-Accelerator-Based Radiosurgery Treatment System in Comparison to the Golden Standard Helical TomoTherapy

Köksal M, Özkan O, Holderried T, Heine A, Brossart P, Gawish A, Scafa D, Sarria GR, Leitzen C, Schmeel LC, Müdder T.Cancers (Basel). 2023 Aug 23;15(17):4220. doi: 10.3390/cancers15174220.PMID: 37686498

Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics

Köksal M, Baumert J, Jazmati D, Schoroth F, Garbe S, Koch D, Scafa D, Sarria GR, Leitzen C, Massoth G, Delis A, Heine A, Holderried T, Brossart P, Müdder T, Schmeel LC.J Cancer Res Clin Oncol. 2023 Aug;149(10):7007-7015. doi: 10.1007/s00432-023-04657-7. Epub 2023 Mar 1.PMID: 36856852

Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy.

Köksal M, Kersting L, Schoroth F, Garbe S, Koch D, Scafa D, Sarria GR, Leitzen C, Heine A, Holderried T, Brossart P, Zoga E, Attenberger U, Schmeel LC.J Cancer Res Clin Oncol. 2023 Aug;149(9):5965-5973. doi: 10.1007/s00432-022-04565-2. Epub 2023 Jan 6.PMID: 36607428

2022

Baseline immune signature score of Tregs × HLA-DR+CD4+ T cells × PD1+CD8+ T cells predicts outcome to immunotherapy in cancer patients.

Mispelbaum R, Hattenhauer ST, Held SAE, Brossart P, Heine A.Front Immunol. 2022 Nov 28;13:1054161. doi: 10.3389/fimmu.2022.1054161. eCollection 2022.PMID: 36518753

Two cases of EBV infection preceding lymphoma.

Saal J, Aboudan B, Brossart P, Heine A.J Cancer Res Clin Oncol. 2022 Oct;148(10):2929-2932. doi: 10.1007/s00432-022-04145-4. Epub 2022 Jun 22.PMID: 35732965

Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors.

Mispelbaum R, Hattenhauer ST, Brossart P, Heine A.Front Immunol. 2022 Sep 8;13:976011. doi: 10.3389/fimmu.2022.976011. eCollection 2022.PMID: 36159812

SARS-CoV-2 PrEP complicates antibody testing after vaccination: a call for awareness.

Monin MB, Marx B, Meffert L, Boesecke C, Rockstroh JK, Strassburg CP, Brossart P, Heine A.Ann Hematol. 2022 Sep;101(9):2089-2090. doi: 10.1007/s00277-022-04859-y. Epub 2022 May 24.PMID: 35608678

Red Blood Cell Distribution Width to Platelet Count Ratio Facilitates Preoperative Prediction of Recurrence in Surgically Treated Chronic Subdural Hematoma.

Güresir Á, Coch C, Heine A, Mass E, Lampmann T, Vatter H, Velten M, Schmitz MT, Güresir E, Wach J.Front Neurol. 2022 May 11;13:884231. doi: 10.3389/fneur.2022.884231. eCollection 2022.PMID: 35645986

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind FG, Ellinger J, Brossart P, Diem S, Schmid S, Joerger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T.J Immunother Cancer. 2022 Mar;10(3):e004024. doi: 10.1136/jitc-2021-004024.PMID: 35292517

Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.

Koerber RM, Held SAE, Vonnahme M, Feldmann G, Wenzel J, Gütgemann I, Brossart P, Heine A.J Cancer Res Clin Oncol. 2022 Mar;148(3):743-748. doi: 10.1007/s00432-021-03777-2. Epub 2021 Sep 16.PMID: 34529129

Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient.

Schlaweck S, Brossart P, Heine A.Ann Hematol. 2022 Jan;101(1):217-218. doi: 10.1007/s00277-021-04403-4. Epub 2021 Jan 12.PMID: 33438048

2021

The Relevance of G-Quadruplexes for DNA Repair.

Linke R, Limmer M, Juranek SA, Heine A, Paeschke K.Int J Mol Sci. 2021 Nov 22;22(22):12599. doi: 10.3390/ijms222212599.PMID: 34830478

Cardiac MRI in Patients with Prolonged Cardiorespiratory Symptoms after Mild to Moderate COVID-19.

Kravchenko D, Isaak A, Zimmer S, Mesropyan N, Reinert M, Faron A, Pieper CC, Heine A, Velten M, Nattermann J, Kuetting D, Duerr GD, Attenberger UI, Luetkens JA.Radiology. 2021 Dec;301(3):E419-E425. doi: 10.1148/radiol.2021211162. Epub 2021 Aug 10.PMID: 34374593

Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study.

Faron A, Isaak A, Mesropyan N, Reinert M, Schwab K, Sirokay J, Sprinkart AM, Bauernfeind FG, Dabir D, Pieper CC, Heine A, Kuetting D, Attenberger U, Landsberg J, Luetkens JA.Radiology. 2021 Dec;301(3):602-609. doi: 10.1148/radiol.2021210814. Epub 2021 Sep 28.PMID: 34581628

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation.

Dold L, Lutz P, Heine A, Weismüller TJ, Strassburg CP, Spengler U.Clin Case Rep. 2021 Sep 5;9(9):e04782. doi: 10.1002/ccr3.4782. eCollection 2021 Sep.PMID: 34504700

Pacritinib protects dendritic cells more efficiently than ruxolitinib.

Heine A, Wolf AM, Schlaweck S, Daecke SN, Brossart P, Wolf D.Exp Hematol. 2021 Aug;100:37-40. doi: 10.1016/j.exphem.2021.06.004. Epub 2021 Jun 25.PMID: 34182006

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells.

Braun C, Schlaweck S, Daecke SN, Brossart P, Heine A.Cancer Immunol Immunother. 2021 Dec;70(12):3693-3700. doi: 10.1007/s00262-021-02988-3. Epub 2021 Jun 25.PMID: 34173009

Tumor rejection in Cblb -/- mice depends on IL-9 and Th9 cells.

Schanz O, Cornez I, Yajnanarayana SP, David FS, Peer S, Gruber T, Krawitz P, Brossart P, Heine A, Landsberg J, Baier G, Wolf D.J Immunother Cancer. 2021 Jul;9(7):e002889. doi: 10.1136/jitc-2021-002889.PMID: 34272310

ROCKing Chronic Graft-Versus-Host Disease.

Heine A, Holderried TAW, Wolf D.J Clin Oncol. 2021 Oct 10;39(29):3308. doi: 10.1200/JCO.21.01081. Epub 2021 Aug 4.PMID: 34347530

Clinical and immunological effects of mRNA vaccines in malignant diseases.

Heine A, Juranek S, Brossart P.Mol Cancer. 2021 Mar 15;20(1):52. doi: 10.1186/s12943-021-01339-1.PMID: 33722265

Cardiac MRI in Suspected Acute COVID-19 Myocarditis.

Luetkens JA, Isaak A, Öztürk C, Mesropyan N, Monin M, Schlabe S, Reinert M, Faron A, Heine A, Velten M, Dabir D, Boesecke C, Strassburg CP, Attenberger U, Zimmer S, Duerr GD, Nattermann J.Radiol Cardiothorac Imaging. 2021 Mar 4;3(2):e200628. doi: 10.1148/ryct.2021200628. eCollection 2021 Apr.PMID: 33969316

Elotuzumab spares dendritic cell integrity and functionality.

Schlaweck S, Strauss L, Daecke S, Brossart P, Heine A.J Cancer Res Clin Oncol. 2021 Jul;147(7):2167-2170. doi: 10.1007/s00432-021-03572-z. Epub 2021 Mar 2.PMID: 33651141

BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells.

De Magis A, Kastl M, Brossart P, Heine A, Paeschke K.BMC Biol. 2021 Mar 11;19(1):45. doi: 10.1186/s12915-021-00986-6.PMID: 33706790

G-quadruplexes: a promising target for cancer therapy.

Kosiol N, Juranek S, Brossart P, Heine A, Paeschke K.Mol Cancer. 2021 Feb 25;20(1):40. doi: 10.1186/s12943-021-01328-4.PMID: 33632214

2020

Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal.

Baumann T, Dunkel A, Schmid C, Schmitt S, Hiltensperger M, Lohr K, Laketa V, Donakonda S, Ahting U, Lorenz-Depiereux B, Heil JE, Schredelseker J, Simeoni L, Fecher C, Körber N, Bauer T, Hüser N, Hartmann D, Laschinger M, Eyerich K, Eyerich S, Anton M, Streeter M, Wang T, Schraven B, Spiegel D, Assaad F, Misgeld T, Zischka H, Murray PJ, Heine A, Heikenwälder M, Korn T, Dawid C, Hofmann T, Knolle PA, Höchst B.Nat Immunol. 2020 May;21(5):555-566. doi: 10.1038/s41590-020-0666-9. Epub 2020 Apr 23.PMID: 32327756

Diffuse Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging.

Luetkens JA, Isaak A, Zimmer S, Nattermann J, Sprinkart AM, Boesecke C, Rieke GJ, Zachoval C, Heine A, Velten M, Duerr GD.Circ Cardiovasc Imaging. 2020 May;13(5):e010897. doi: 10.1161/CIRCIMAGING.120.010897. Epub 2020 May 13.PMID: 32397816

2019

The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s Lymphoma.

Holderried TAW, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D.Bone Marrow Transplant. 2019 Oct;54(10):1662-1667. doi: 10.1038/s41409-019-0498-0. Epub 2019 Mar 4.PMID: 30833743

2018

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab.

Schwab KS, Kristiansen G, Schild HH, Held SEA, Heine A, Brossart P.Case Rep Oncol. 2018 Jan 4;11(1):17-20. doi: 10.1159/000485562. eCollection 2018 Jan-Apr.PMID: 29515404

2017

Prolonged IKKβ Inhibition Improves Ongoing CTL Antitumor Responses by Incapacitating Regulatory T Cells.

Heuser C, Gotot J, Piotrowski EC, Philipp MS, Courrèges CJF, Otte MS, Guo L, Schmid-Burgk JL, Hornung V, Heine A, Knolle PA, Garbi N, Serfling E, Evaristo C, Thaiss F, Kurts C.Cell Rep. 2017 Oct 17;21(3):578-586. doi: 10.1016/j.celrep.2017.09.082.PMID: 29045828

Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways.

Kotthoff P, Heine A, Held SAE, Brossart P.Sci Rep. 2017 Jul 3;7(1):4522. doi: 10.1038/s41598-017-04558-z.PMID: 28674449

Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Heine A, Flores C, Gevensleben H, Diehl L, Heikenwalder M, Ringelhan M, Janssen KP, Nitsche U, Garbi N, Brossart P, Knolle PA, Kurts C, Höchst B.Oncoimmunology. 2017 Jun 16;6(8):e1338995. doi: 10.1080/2162402X.2017.1338995. eCollection 2017.PMID: 28920004

Generation and functional characterization of MDSC-like cells.

Heine A, Held SAE, Schulte-Schrepping J, Wolff JFA, Klee K, Ulas T, Schmacke NA, Daecke SN, Riethausen K, Schultze JL, Brossart P.Oncoimmunology. 2017 Feb 23;6(4):e1295203. doi: 10.1080/2162402X.2017.1295203. eCollection 2017.PMID: 28507805

2016

The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.

Heine A, Schilling J, Grünwald B, Krüger A, Gevensleben H, Held SA, Garbi N, Kurts C, Brossart P, Knolle P, Diehl L, Höchst B.Cancer Immunol Immunother. 2016 Mar;65(3):273-82. doi: 10.1007/s00262-015-1790-5. Epub 2016 Jan 19.PMID: 26786874

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J.Medicine (Baltimore). 2016 May;95(20):e3355. doi: 10.1097/MD.0000000000003355.PMID: 27196445

Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products.

Berens C, Heine A, Müller J, Held SA, Mayer K, Brossart P, Oldenburg J, Pötzsch B, Wolf D, Rühl H.Cytotherapy. 2016 Oct;18(10):1325-31. doi: 10.1016/j.jcyt.2016.06.014. Epub 2016 Aug 1.PMID: 27491794

2015

Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.

Rittig SM, Haentschel M, Weimer KJ, Heine A, Müller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P.Oncoimmunology. 2015 Oct 29;5(5):e1108511. doi: 10.1080/2162402X.2015.1108511. eCollection 2016 May.PMID: 27467913

Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.

Koerber RM, Held SAE, Heine A, Kotthoff P, Daecke SN, Bringmann A, Brossart P.Exp Hematol Oncol. 2015 Aug 5;4:21. doi: 10.1186/s40164-015-0016-z. eCollection 2015.PMID: 26251761

Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors.

Held SA, Heine A, Kesper AR, Schönberg K, Beckers A, Wolf D, Brossart P.Oncoimmunology. 2015 Jul 1;5(1):e1065368. doi: 10.1080/2162402X.2015.1065368. eCollection 2016.PMID: 26942083

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.

Heine A, Held SA, Daecke SN, Riethausen K, Kotthoff P, Flores C, Kurts C, Brossart P.PLoS One. 2015 Jun 4;10(6):e0128897. doi: 10.1371/journal.pone.0128897. eCollection 2015.PMID: 26042424

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

Schönberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, Manser AR, Uhrberg M, Verbeek W, Koschmieder S, Brümmendorf TH, Brossart P, Heine A, Wolf D.Cancer Res. 2015 Jun 1;75(11):2187-99. doi: 10.1158/0008-5472.CAN-14-3198. Epub 2015 Apr 1.PMID: 25832652

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D.Br J Haematol. 2015 Jun;169(6):824-33. doi: 10.1111/bjh.13373. Epub 2015 Mar 30.PMID: 25824483

A party of three: iNKT cells in GVHD prevention.

Heine A, Brossart P.Blood. 2015 May 28;125(22):3374-5. doi: 10.1182/blood-2015-04-636282.PMID: 26022054

2014

Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning.

Wolf D, Heine A, Brossart P.Oncoimmunology. 2014 Jan 1;3(1):e27588. doi:10.4161/onci.27588. Epub 2014 Jan 3.PMID: 24800168

2013

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Heine A, Brossart P, Wolf D.Blood. 2013 Nov 28;122(23):3843-4. doi: 10.1182/blood-2013-10-531103.PMID: 24288410

Advances in immunotherapy of chronic myeloid leukemia CML.

Held SA, Heine A, Mayer KT, Kapelle M, Wolf DG, Brossart P.Curr Cancer Drug Targets. 2013 Sep;13(7):768-74. doi: 10.2174/15680096113139990086.PMID: 23906051

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P.Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14.PMID: 23770777

Regression of liver metastases after treatment with oxaliplatin/capecitabine and development of a progressive multifocal leukoencephalopathy in a patient with advanced thymoma.

Heine A, Schmiedel A, Menschik T, Held SA, Erdmann C, Brossart P.J Clin Oncol. 2013 Apr 20;31(12):e203-5. doi: 10.1200/JCO.2012.43.8150. Epub 2013 Mar 18.PMID: 23509314

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.

Held SA, Duchardt KM, Tenzer S, Rückrich T, von Schwarzenberg K, Bringmann A, Kurts C, Schild H, Driessen C, Brossart P, Heine A.Cancer Immunol Immunother. 2013 Apr;62(4):715-26. doi: 10.1007/s00262-012-1373-7. Epub 2012 Nov 25.PMID: 23184338

2011

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P.Mol Ther. 2011 May;19(5):990-9. doi: 10.1038/mt.2010.289. Epub 2010 Dec 28.PMID: 21189474

Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone.

Kock G, Bringmann A, Held SA, Daecke S, Heine A, Brossart P.Blood. 2011 Mar 31;117(13):3569-74. doi: 10.1182/blood-2010-08-302224. Epub 2011 Feb 4.PMID: 21296999

2010

RNA vaccines in cancer treatment.

Bringmann A, Held SA, Heine A, Brossart P.J Biomed Biotechnol. 2010;2010:623687. doi: 10.1155/2010/623687. Epub 2010 Jun 1.PMID: 20625504

2009

Immunotherapy in renal cell carcinoma.

Heine A, Holderried TA, Brossart P.Immunotherapy. 2009 Jan;1(1):97-107. doi: 10.2217/1750743X.1.1.97.PMID: 20635977

2008

Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells.

Grünebach F, Erndt S, Häntschel M, Heine A, Brossart P.Cancer Immunol Immunother. 2008 Oct;57(10):1483-91. doi: 10.1007/s00262-008-0486-5. Epub 2008 Feb 27.PMID: 18301890

Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells.

Yokoyama Y, Grünebach F, Schmidt SM, Heine A, Häntschel M, Stevanovic S, Rammensee HG, Brossart P.Clin Cancer Res. 2008 Sep 1;14(17):5503-11. doi: 10.1158/1078-0432.CCR-07-4041.PMID: 18765542

2006

Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses.

Heine A, Grünebach F, Holderried T, Appel S, Weck MM, Dörfel D, Sinzger C, Brossart P.Mol Ther. 2006 Feb;13(2):280-8. doi: 10.1016/j.ymthe.2005.08.019. Epub 2005 Oct 10.PMID: 16219490

2005

Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.

Dörfel D, Appel S, Grünebach F, Weck MM, Müller MR, Heine A, Brossart P.Blood. 2005 Apr 15;105(8):3199-205. doi: 10.1182/blood-2004-09-3556. Epub 2004 Dec 23.PMID: 15618468

Research Gate

Find all our publications on Research Gate.

Impressum • Datenschutzerklärung

Impressum

Datenschutzerklärung